Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$101.88 USD

101.88
10,180,742

-0.44 (-0.43%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Investor focus is likely to be on updates regarding Fusion Pharmaceuticals' (FUSN) pipeline candidates on the fourth-quarter conference call.

Kinjel Shah headshot

Pharma Stock Roundup: Pfizer's Velsipity Receives EU Nod, ABBV Gets New CEO & More

by Kinjel Shah

European Commission approves Pfizer's (PFE) Velsipity ulcerative colitis (UC) pill. AbbVie (ABBV) appoints Robert A. Michael as the new CEO.

Moderna (MRNA) Beats on Q4 Earnings & Sales, Reiterates View

by Zacks Equity Research

Moderna (MRNA) beats expectations for earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Zacks Analyst Blog Highlights Merck, ServiceNow, Blackstone, Gilead Sciences and Diageo

by Zacks Equity Research

Merck, ServiceNow, Blackstone, Gilead Sciences and Diageo are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Merck, ServiceNow & Blackstone

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), ServiceNow, Inc. (NOW) and Blackstone Inc. (BX).

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?

by Zacks Equity Research

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow

by Zacks Equity Research

Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.

Sweta Killa headshot

A Look at Pharma ETFs After Q4 Earnings

by Sweta Killa

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Kinjel Shah headshot

Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals

by Kinjel Shah

Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.

Bristol Myers' (BMY) Opdivo Label Expansion Filings Get Accepted

by Zacks Equity Research

Bristol Myers (BMY) announces the acceptance of its regulatory filings for the perioperative Opdivo regimen to treat a lung cancer indication in the United States and EU.

AstraZeneca (AZN) Q4 Earnings & Sales Miss Estimates, Stock Down

by Zacks Equity Research

AstraZeneca (AZN) marginally misses fourth-quarter estimates for earnings and sales. It expects revenues and EPS to increase at a low double-digit to low teens percentage in 2024 at CER.

Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3B

by Zacks Equity Research

Merck's (MRK) Animal Health unit is set to strengthen its position with the acquisition of Elanco Animal Health's aqua business for $1.3 billion. The transaction is expected to close by mid-2024.

Stock Market News for Feb 2, 2024

by Zacks Equity Research

U.S. stocks closed higher on Thursday as they tried to recover from a massive selloff in the previous session after the Federal Reserve held interest rates steady but also said that a rate cut in March is unlikely.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates

by Kinjel Shah

Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.

Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View

by Zacks Equity Research

Merck (MRK) beats Q4 estimates for earnings but misses the mark on sales. The company issues an encouraging 2024 guidance. Stock rises in pre-market.

Merck (MRK) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Merck (MRK) Beats Q4 Earnings Estimates

by Zacks Equity Research

Merck (MRK) delivered earnings and revenue surprises of 133.33% and 0.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Powell Dubious on March Cut, Markets Slide

by Mark Vickery

Indices jumped higher on the Fed's release initially, but in terms of forecasting a March cut, Fed Chair Powell said that this was "not the most-likely case."

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) Q4 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.

Pfizer (PFE) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of 152.63% and 0.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?

by Zacks Equity Research

We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.

Countdown to Merck (MRK) Q4 Earnings: Wall Street Forecasts for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.